Search

Displaying results 3881 - 3890 of 5302 in total
  1. Drug

    DS-2325a

    go.drugbank.com/drugs/DB18134
    Investigational

    DS-2325a is an inhibitor of kallikrein 5 under development for the treatment of Netherton Syndrome.

  2. Drug

    LB-P8

    go.drugbank.com/drugs/DB18535
    Investigational

    LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).

  3. Drug

    MCMV5322A

    go.drugbank.com/drugs/DB17763
    Investigational

    MCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV3068A] to form RG7667.[A259362]

  4. Drug

    MCMV3068A

    go.drugbank.com/drugs/DB17764
    Investigational

    MCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV5322A] to form RG7667.[A259362]

  5. Drug

    Adapalene

    go.drugbank.com/drugs/DB00210
    ApprovedInvestigational

    [A193521] [Tazarotene] is more efficacious than adapalene but is designated as pregnancy category X and hence is contraindicated in pregnant women. … [A193518] Adapalene can also be combined with benzoyl peroxide (BPO), which possesses bactericidal properties[A193524], and either adapalene alone, or adapalene BPO combination products, are commonly used

  6. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo.

    Synonyms: AN-9
  7. Drug

    Brifentanil

    go.drugbank.com/drugs/DB09172
    ExperimentalIllicit

    Brifentanil (also known as A-3331) is an analog of fentanyl, a potent opioid. This drug is classified as an opioid analgesic and was developed in the early 1990s.

  8. Drug

    Faricimab

    go.drugbank.com/drugs/DB15303
    ApprovedInvestigational

    [L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995] Faricimab is an IgG<sub>1</sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic

  9. Drug

    Cannabinor

    go.drugbank.com/drugs/DB05048
    Experimental

    Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.

  10. Drug

    Danofloxacin

    go.drugbank.com/drugs/DB11393
    ExperimentalVet approved

    Danofloxacin is an antibiotic agent from the family of the fluoroquinolones used in veterinary medicine.